‘The paradigm shift from cost-based pricing to market-based pricing has been long…
India’s search for a universal formula to fix prices of essential drugs appears to have been addressed with the new pharma policy…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
‘A win-win policy for all stakeholders’
DPCO 2013 is truly a win-win move for the patient, pharma industry and the Government. Indian pharma industry generates…
’DPCO 2013 will equally affect domestic as well multinational pharma companies’
The DPCO 2013 aims to put in place a regulatory framework for pricing of drugs so as to ensure availability of 'essential…
’Longer-term growth prospects’
ICRA expects that the latest proposed market-based pricing mechanism for the Indian pharma industry would impact near term…
‘This pricing policy would help on affordability issue’
The impact on the pharma industry revenues will be limited for around 12-18 months, post which the product portfolio will evolve…
‘It would be too early to call this policy a boon or bane’
The NELM policy is adopted to strike a balance between the growing pharma industry of the nation and offer accessibility and…
‘Government should also focus on affordability and access’
Whilst the move to market-based pricing is positive, the Government must focus on the real issue which is affordability and access…
Nutraceuticals on the move
Suhas Wadwalkar, Vice President — Corporate Affairs, Premier Nutraceuticals, focuses on the fresh and emerging segment of…
Whistleblower Protection in India Delay in framing legal enactment will harm the public interest
Rajdutt Shekhar Singh, Principal Associate, Singh and Associates gives an insight about the protection which needs to be provided…
‘Companies are able to benefit without the need to make a significant investment’
Ram Kumar Pichai, General Manager - Microsoft Office Division talks to Usha Sharma, about the service, its USP and its importance…